Cardiologists have warned for years that healthy adults with no family history of CVD should not be taking low-dose aspirin every day—but as the saying goes, old habits die hard. 

Many PAD patients do not even know they have the disease until it is too late, leading to unnecessary amputations and increasing the risk of other adverse patient outcomes. Awareness is especially limited among Black and Hispanic adults, experts warn, creating an added sense of urgency when looking to accelerate patient education efforts.

Boston-based Amplitude Vascular Systems is busy investigating the performance of its Pulse IVL platform in a wide variety of patient populations.

The new blood test from Roche Diagnostics measures Lp(a) in terms of nanomoles per liter (nmol/L) as opposed to milligrams per deciliter (mg/dL).

In addition, researchers noted, five-year mortality was inferior for patients on Medicaid when compared to patients with any other type of insurance. 

Johnson & Johnson MedTech's Varipulse PFA system has been linked to multiple reports of "neurovascular events" in patients. The company hopes to share more information in the days ahead. 

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

Approximately 800,000 strokes occur each year in the United States alone. A majority of people survive, due in part to key advances in patient care over the years, but they often go forward without receiving the long-term help they need to recover and thrive.